Evidence map›Paper›PMID 32694043›Full record

Trial reportTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis2020

Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study.

Hassan Abolghasemi, Peyman Eshghi, Abdol Majid Cheraghali, Abbas Ali Imani Fooladi, Farzaneh Bolouki Moghaddam, Sina Imanizadeh, Matin Moeini Maleki, Mohammad Ranjkesh, Mohammad Rezapour, Ali Bahramifar and 17 more

Registry-linked trialAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05046652 (Effectiveness of Convalescent Plasma Therapy in 8 Non-Intubated COVID-19 Patients in Indonesia), which is not on this map. Cited by 119 papers, 21 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 21 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05046652 completednot on this map

Effectiveness of Convalescent Plasma Therapy in 8 Non-Intubated COVID-19 Patients in Indonesia: A Case Series

TypeobservationalSponsorMaranatha Christian UniversityRan2020 to 2020Enrolled8ConditionsInfectious DiseaseArmsConvalescent Plasma Therapy
3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 21 syntheses or guidelines pooled it.

  1. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Pooled it
  4. Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Effect of convalescent blood products for patients with severe acute respiratory infections of viral etiology: A systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Pooled it
  19. Pooled it
  20. Pooled it

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Hassan AbolghasemiApplied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Peyman EshghiPediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences and Iran Blood Transfusion Organization, Tehran, Iran.
Abdol Majid CheraghaliSchool of Pharmacy and Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address: majidcheraghali@gmail.com.
Abbas Ali Imani FooladiApplied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Farzaneh Bolouki MoghaddamStudent Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Sina ImanizadehStudent Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Matin Moeini MalekiStudent Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Mohammad RanjkeshStudent Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Mohammad RezapourStudent Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Ali BahramifarTrauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Behzad EinollahiNephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Mohammad Javad HosseiniMolecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Nematollah Joneidi JafariHealth Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Mohamad NikpouraghdamNephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Nariman SadriDarman Ara PJS Company, Tehran, Iran.
Mokhtar TazikDarman Ara PJS Company, Tehran, Iran.
Shanaz SaliInfectious Disease and Tropical Medicine Research Center, Shahid Behesti University of Medical Sciences, Tehran, Iran.
Shamsi OkatiHigh Institute for Research and Education in Transfuion Medicine, Tehran, Iran.
Elham AskariNational Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Payam TabarsiNational Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Jafar AslaniChemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Ehsan SharifipourNeuroscience Research Center of Qom University of Medical Science, Qom, Iran.
Mohammad Hossein JarahzadehDepartment of Anesthesiology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Nastaran KhodakarimDepartment of Medical Oncology and Hematology, Iran University of Medical Sciences, Tehran, Iran.
Mahmood SalesiChemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Ramezan JafariChemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Samira ShahverdiDepartment of Radiology, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. One hundred eighty-nine COVID-19 positive patients including 115 patients in plasma therapy group and 74 patients in control group, registered in the hospitals with confirmed COVID-19 infection, entered this multi-center clinical study. Comparison of outcomes including all-cause mortality, total hospitalization days and patients' need for intubation between the two patient groups shows that total of 98 (98.2 %) of patients who received convalescent plasma were discharged from hospital which is substantially higher compared to 56 (78.7 %) patients in control group. Length of hospitalization days was significantly lower (9.54 days) in convalescent plasma group compared with that of control group (12.88 days). Only 8 patients (7%) in convalescent plasma group required intubation while that was 20 % in control group. This clinical study provides strong evidence to support the efficacy of convalescent plasma therapy in COVID-19 patients and recommends this treatment for management of these patients. Clinical efficacy, immediate availability and potential cost effectiveness could be considered as main advantages of convalescent plasma therapy.

Indexed as

AdultAgedAged, 80 and overCOVID-19COVID-19 SerotherapyFemaleHumansImmunization, PassiveMaleMiddle AgedSARS-CoV-2Treatment OutcomeYoung AdultClinical trialConvalescent plasmaCOVID-19Hospital stayMortality rate

Identifiers

PMID32694043
PMCPMC7362821

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.